



Grant Agreement no. 829010



Call: H2020-FETOPEN-2018-2020
Topic: FETOPEN-01-2018-2019-2020
Type of Action: RIA (Research and Innovation action)
Name of Lead Beneficiary: CSIC, Spain
Project Start Date: 1st May 2019
Project Duration: 48 months

DELIVERABLE 4.2: *Communication and Dissemination strategy*

Due date of Deliverable: October 31st, 2019
Actual Submission Date: October 31st, 2019
Responsible partner: BNN, Austria
Report authors: Falk, Ladenhauf, Jagersbacher, Schimpel, Halbedel
Type¹: R
Dissemination Level²: PU

¹ **Type:** Use one of the following codes (in consistence with the Description of the Action):

- R: Document, report (excluding the periodic and final reports)
- DEM: Demonstrator, pilot, prototype, plan designs
- DEC: Websites, patents filing, press & media actions, videos, etc.
- OTHER: Software, technical diagram, etc.

² **Dissemination level:** Use one of the following codes (in consistence with the Description of the Action)

- PU: Public, fully open, e.g. web
- CO: Confidential, restricted under conditions set out in the Model Grant Agreement
- CI: Classified, information as referred to in Commission Decision 2001/844/EC

DELIVERABLE D4.2: *Communication and Dissemination strategy*

Table of Contents

1	Introduction	5
1.1	PRIME project in a nutshell.....	5
1.2	Update of the communication and dissemination strategy	6
2	Target audience of PRIME	7
2.1	Project internal stakeholders.....	7
2.2	Project external stakeholders.....	7
3	Internal communication	10
3.1	Overall project cooperation	10
3.2	Reporting (deliverables, reports).....	16
3.2	Meetings.....	17
4.	External communication and dissemination	18
4.1	Visual identity	18
4.2	Communication and Dissemination activities	19
5.	Publications.....	23
5.1	Contractual framework for publications	23
6	Conclusions	23
	ANNEX 1: Recent and future activities by PRIME partners.....	24
	ANNEX 2: Stakeholder Analysis template.....	28
	ANNEX 3: Non exhaustive list of strategic/financial investors	29
	ANNEX 4: Non exhaustive list of companies.....	30



Document History

Version	Date	Authors/ who took action	Comment	Modifications made by
1	October 2 nd , 2019	BNN	Internal review finalised	
2	October 2 nd , 2019	BNN	Draft version circulated within consortium (PIs)	
3	October 10 th , 2019	CSIC	Draft reviewed by coordinator	
4	October 18 th , 2019	BNN	2 nd draft circulated to the coordinator	
5	October 25 th , 2019	CSIC	2 nd Draft reviewed by coordinator	
6	October 28 th , 2019	BNN	3 rd draft circulated to the PIs	
7	October 29 th , 2019	CSIC	Draft commented by coordinator	
8	October 30 th , 2019	BNN	Final version sent to coordinator for submission	
9	October 31 st , 2019	CSIC	Final version submitted to EC	



List of Abbreviations

CA	Consortium Agreement
EC	European Commission
EU	European Union
GA	Grant Agreement
GB	General Board
KOM	Kick-off meeting
M	Month
PC	Project Coordinator
PI	Principal Investigator
SO	Specific Objective
WP	Work Package
WPL	Work Package Leader



1 INTRODUCTION

The PRIME project has been awarded funding by the European Commission, which requires the whole consortium to communicate the project and disseminate its results to a wider public community. This document will help all project participants to face the challenge of how to disseminate to maximum effect with the given resources.

Annex I of the Grant Agreement (GA) addresses all communication and dissemination efforts under WP 4 “Dissemination and exploitation of results” (especially Tasks 4.1 “Public website”, 4.3 “Communication and dissemination management”, and 4.4 “Coordination of scientific publication and Open Access”). Main actions will include the operation of the project website, the active participation at conferences, publication activities and other written communication and dissemination efforts such as a project fact sheet or newsletter contributions.

This document shall be understood as supporting means to fulfil all obligations agreed within the GA, explicitly Articles 29, 38 (Dissemination of results – open access – visibility of EU funding, promoting the action) and 52 (communication between the parties).

1.1 PRIME project in a nutshell

Microfluidic devices manipulate tiny amounts of fluid enabling cost-effective, fast, accurate and high throughput analytical assays. Progress in Microfluidics has huge impact in environmental pollution monitoring, biohazard detection and biomedicine, contributing to the development of new tools for drug screening, biological studies, point-of-care diagnostics and personalized medicine. Despite this huge potential, Microfluidics market growth is heavily constrained by the complexity and high prices of the required large-scale off-chip equipment and its operational cost. PRIME will use additive manufacturing of responsive materials for the direct implementation and integration of smart valves and pumps in a microfluidic chip. Additionally, new ultra-sensitive and selective sensors will be embedded in the chip and readable with light. The final device will be remotely addressed and read using simple photonic elements that can be integrated in compact, portable and cheap operation&read devices. PRIME goes beyond the state-of-the-art generating a robust platform to create a new generation of active, tubeless and contactless microfluidic chips effectively changing the currently established paradigm. PRIME will develop a radically new platform that: i) integrates all the required responsive materials and elements in the chip, effectively providing it with all the fluidic and sensing functions, ii) uses compatible materials and manufacturing technologies making future industrial production viable and cost-effective, iii) allows to implement with extensive freedom of design a plethora of new smart-integrated and easy-to-operate microfluidic chips. PRIME will thus narrow the gap between Microfluidics and non-specialized laboratories and end-users enabling the spread and penetration of the technology in diverse application fields as well as its geographical expansion to areas where large equipment is difficult to transport or resources are scarce.



1.2 Update of the communication and dissemination strategy

The PRIME Communication and dissemination strategy will be a living document that will be updated along the project, in order to adapt to the requirements of its evolution. The first phase of proper communication and dissemination will cover the submission of this deliverable and detailed planning of the implementation of the actions. With ongoing communication of the project, dissemination activities will start in the second phase, together with constant evaluation of the targeted measures. The third phase will play into the considerations towards a successful exploitation of the action.

Official updates of the Communication and Dissemination strategy will take place at M12, M18, M24, M30, M36, M42, and M48.



2 TARGET AUDIENCE OF PRIME

Asking all partners for input, PRIME has identified its relevant stakeholders, which are divided into internal and external target groups and further described in the following paragraphs.

2.1 Project internal stakeholders

2.1.1 Consortium participants (GA/CA signed)

The PRIME consortium consists of 6 partners from 4 different European countries (Spain, the Netherlands, Germany, and Austria), 5 from Academia and 1 SME. To ensure successful dissemination and exploitation, it is inevitable to foster internal communication and keep the motivation high, both regarding research efforts and engagement in the process of spreading the project's results.

2.1.2 European Commission

The European Commission represents the European Union as contractual partner and funding body of the grant agreement and therefore is a major stakeholder. The Project Officer is the designated contact point for the Project Coordinator (Carlos Sánchez Somolinos).

2.2 Project external stakeholders

The newly developed technology is generally targeting the huge analytical, biotechnology and medical technology markets. More specifically the envisaged technology will mainly address diverse application fields ranging from biological basic research and drug testing studies in the biomedical field to environmental, food and water assays, as well as their expansion to geographical areas in the world where economical resources are limited or locations (including outer space) where bringing heavy and bulky devices is difficult and/or expensive.

The huge market potential of results gained by the project might impact the overall MF market in general, however, it is important to identify the external stakeholders starting from the existing frameworks of each participant. These networks, consisting of all sorts of stakeholder groups will play a crucial role in the communication and dissemination (and consequently in successful implementation of exploitation efforts) implementation. ANNEX 2 presents the basis template that will be internally used to continuously monitor and gather stakeholders, both organisations and individuals. The implementation plan of this strategy foresees a mapping of all relevant stakeholders until M8 (12/19). The stakeholder analysis will serve as a main source for channelling the proposed communication and dissemination efforts, and will determine, where on the continuum regarding Power/Interest and Support/resistance these stakeholders are placed. Also it will monitor key factors (e.g. financial interests, business interests) and planned tailored



engagement strategies. Table 1 depicts an initial non exhaustive list as a basis for the detailed mapping and categorisation of relevant stakeholders.

Table 1: Basic PRIME stakeholders list (Non-exhaustive)

Stakeholder group	Organisations/companies/bodies
Healthcare & Governmental organizations	Regulatory / standardisation bodies, lobby groups, industry organisations, local/national authorities
Investors	e.g.: Financial vs. strategic, Banks & Government Agencies, Angel Investors, Angel Groups, Accelerators & Incubators, Venture Capital Firms, Corporate Investors (also see ANNEX 3: Non exhaustive list of investors)
Companies (chip manufacturers, system integrators, R&D companies, diagnostic companies, etc.)	e.g.: Becton Dickinson (https://moleculardiagnosics.bd.com), BioFluidix GmbH (http://www.biofluidix.com/?gclid=EAlaIqobChMli527tbi-5QIVxZTVCh0gOg5OEAAAYASAAEgJALvD_BwE), PerkinElmer (https://www.perkinelmer.com/de/corporate/what-we-do/markets/life-sciences.html), ELVEFLOW (https://www.elveflow.com/), Daktari Diagnostics (http://daktaridx.com/), Dolomite Microfluidics (https://www.dolomite-microfluidics.com/), Fluidigm (https://www.fluidigm.com/), Stratec (https://www.stratec.com/home), Cytosurge, Thinxxs (https://www.thinxxs.de/?gclid=EAlaIqobChMlo7iEyLm-5QIVDeR3Ch3-bgEmEAAYBCAAEgIlnfD_BwE), micronit (https://www.micronit.com/?gclid=EAlaIqobChMI2ICcqrq-5QIV1eN3Ch1MtwCoEAAYAiAAEgLUK_D_BwE), microfluidics Chipshop (https://www.microfluidic-chipshop.com/), z-microsystems (http://www.z-microsystems.com/en/home/), Abbott Point of Care Inc (https://www.pointofcare.abbott/int/en/home), Achira Labs Pvt Ltd (https://achiralabs.com/), ACAMP: Alberta Centre For Advanced Mnt Products (https://www.acamp.ca/capabilities/microfluidics/), Fluigent (https://www.fluigent.com/), GE Healthcare (https://www.ge.com/research/project/microfluidic-flow-cell-cell-analysis), ibidi GmbH (https://ibidi.com/), Lunaphore Technologies (https://www.lunaphore.ch/), mFluidx (https://www.mfluidx.com/), DENZ Bio-Medical (https://www.denz-bio-medical.com/), Qiagen GmbH (https://www.qiagen.com/us/), Roche Diagnostics Corporation (https://diagnostics.roche.com/global/en/home.html#selectProfile), Siemens Healthcare Diagnostics (https://www.siemens-healthineers.com/at/), Tecan Systems Inc (https://www.tecan.com/), Genspeed Biotech GmbH (https://www.genspeed-biotech.com/), Weidmann Plastics (https://www.weidmann-medical.com/), CapitalBio (http://www.capitalbiotech.com/en/index.html), Tecnisco (http://www.tecnisco.co.jp/en/), Micralyne (https://www.micralyne.com/applications/biomed-mems/microfluidic-chips/), Little things factory (https://www.ltf-gmbh.com/home_de.html), Abaxis (https://www.abaxis.com/), Great Basin Scientific (https://gbscience.com/),



	Agilent Technologies (https://www.agilent.com/), Bio-Rad (https://www.bio-rad.com/) (also see ANNEX 4: Non exhaustive list of companies)
Internal project stakeholders	European commission, project participants
Scientific community	Students, Higher education institutions, networks/associations, research institutions, National Research Agencies
Society / Wider public	Potential end users (customers), NGOs (WHO, environmental), Patient groups (e.g. rare diseases),
Application fields (Interest groups)	Environmental pollution monitoring, food and water monitoring, biohazard detection, biomedicine, drug screening, biological studies, point-of-care diagnostics personalized medicine, 3 rd world countries, (bio)chemical analysis, clinical research, drug screening
Media world	Journalists, local TV and media stations, Popular science magazines, Journals, etc.



3 INTERNAL COMMUNICATION

3.1 Overall project cooperation

For the overall success of PRIME it is important that communication between all participants is transparent and open so that each participant is kept up-to-date on work progress, next steps, outcomes of meetings and task allocation.

3.1.1 File exchange and data storage

PRIME has implemented an easy-to-use, web-based, safe internal communication platform within its project website (<https://www.project-prime.eu/member-area/>). This file exchange and data storage platform contains:

- Contractual documents (GA, CA)
- Contact details of all participants
- Logos and templates
- Meeting minutes and reports
- Deliverables
- Others (Scientific documents shared within the technical work packages)

Project participants can register themselves with their email address to the restricted area to have access to all uploaded content. The self-registration via email is followed by a confirmation process, coordinated by the BNN team. If the registered contact does not appear in the project contact list, BNN will contact the coordinator to clarify approval/denial of the registration request. This will ensure that no information is available for unauthorised personnel.

The data stored in the secure area of PRIME website must be handled with the utmost discretion by the PRIME project partners. The publication and/or disclosure of the data of the secure area to third parties is prohibited.

PRIME partners must respect the PRIME privacy policy and the General Data Protection Regulation

([https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679R\(02\)&from=DE](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679R(02)&from=DE)).





The following structure for the platform is proposed to be implemented to ensure sound file management:

- Contractual documents
- Work packages
 - WP1
 - Deliverable reports (final version) and meeting documents (agenda, minutes, presentations)
 - WP2
 - Deliverable reports (final version) and meeting documents (agenda, minutes, presentations)
 - WP3
 - Deliverable reports (final version) and meeting documents (agenda, minutes, presentations)
 - WP4
 - Deliverable reports (final version) meeting documents (agenda, minutes, presentations)
 - WP5
 - Deliverable reports (final version) and meeting documents (agenda, minutes, presentations)
- Contact details
- Logos
- Templates
- Action plans
- Dissemination documents (abstracts, posters, presentation-slides, press releases, etc.)
- Meetings
 - Kick-off meeting
 - Consortium meeting documents (agenda, minutes, presentations)
 - Review meeting documents (agenda, minutes, presentations)
- Reporting
 - Periodic reports




Screenshots of PRIME secure area:





The screenshot shows the PRIME website's 'Contractual documents' page. The header includes the PRIME logo and navigation links: PROJECT, SCIENTIFIC RESULTS, BENEFICIARIES, EVENTS, and MEETINGS. The breadcrumb trail is 'Home » Restricted Area » Contractual documents'. The main heading is 'Contractual documents'. Below it, there are two document icons with labels: 'PRIME Grant agreement' and 'PRIME Consortium agreement'.




The screenshot shows the PRIME website's 'Work packages' page. The breadcrumb trail is 'Home » Work packages'. The main heading is 'Work packages'. Below the heading, there is a paragraph: 'Here you find deliverable reports and meeting documents for all work packages.' To the right, there is a list of work packages:

- **WP1**
Deliverable Reports and meeting documents
- **WP2**
Deliverable Reports and meeting documents
- **WP3**
- **WP4**
- **WP5**



Home » [Restricted Area](#) » Contact details

Contact details

 [Current partner list](#)





Home » [Restricted Area](#) » Logos

Logos



Home » [Restricted Area](#) » Templates

Templates

-  [Agenda template](#)
-  [Deliverable template](#)
-  [Deliverable timeline](#)
-  [Minutes template](#)



Home » Restricted Area » Meetings


Meetings

- Kick-off meeting
- Review meeting documents
- Consortium meeting documents

Home » Restricted Area » Meetings » Kick-off meeting

Kick-off meeting

PRIME-KICKOFF-MINUTES



The following procedure of uploading documents is proposed to ensure full security and order of all documents and its underlying structure:

- Project participants send a formless email containing the documents to be uploaded to prime@bnn.at, indicating the intended destination folder.
- The email will be received by BNN personnel and the PRIME coordinator, and uploaded by the BNN team within 24 hours on business days.

A notice to all PIs and listed contacts (both registered and non-registered to the restricted area) will be given, informing about a new upload after the storage of the document.

Management of data arising from the project research has been described in deliverable 4.3 (Data Management Plan).

3.1.2 Email / telephone

Along with the platform and meetings in-person, the PRIME consortium will use the following communication channels: e-mails and phone calls for regular and daily communication and (video) conference calls in order to enhance team work between physical meetings.



3.2 Reporting (deliverables, reports)

A crucial content of the internal communication plan is reflected in the reporting activities of the project. There are mainly 2 different official paths of sharing consistent information about the work of progress between the partners and the EC:

3.2.1 Deliverables

The list of deliverables can be eyed up in the Grant agreement (GA) (page 88 f.).

Review process for PRIME deliverables

All deliverables prepared by the PRIME consortium, before being submitted to the European Commission, must undergo a project internal review. This review process applies to the deliverables defined in the project's description of work. Each deliverable is assigned a lead partner in the GA, the lead partner referred on the deliverable editor hereafter. The review process is organised in 3 main phases:

1. Review by coordinator and involved partners
2. Review by PIs
3. Submission of deliverable by the coordinator

These three phases are further organized in different tasks:

1. A reminder will be sent by the project manager to the task leader about the preparation of the deliverable [8 weeks before due date].
2. The task leader sends an almost finished draft (already including partners involved contributions) to the coordinator and partners involved [5 weeks before due date].
3. The content will be checked by the partners concerned and by the coordinator [1 week after sending the draft].
4. The task leader sends a final draft with the comments of the coordinator and partners concerned to be reviewed by the PIs [3 weeks before due date].
5. Content will be reviewed by the PIs [1 week after sending the draft].
6. With the feedback from the PIs, the task leader prepares the final version. If the changes made are extensive, the deliverable will be circulated once more to inform the consortium and ask for approval.
7. The task leader sends the coordinator the final deliverable [1 week before due date].



8. The coordinator submits the deliverable to the EC [submission date].

These tasks are carried out by email. The deliverable template can be found on the internal communication platform.

3.2.2 Periodic reports / Final report

According to the reporting period as defined in the GA, a report demonstrating scientific work progress, and management and financial issues will be submitted to the EC after month 12, 30 and 48. Therefore, all partners and WPL will submit a report to the coordinator strictly in accordance with the guidelines and rules provided by the EC. The coordinator will verify these reports and then submit them to the EC.

3.2 Meetings

The project will be governed by the General Board (GB), with one representative of each partner institution and meeting, at least, yearly (see table 2). In addition to the kick-off meeting and the 4 yearly physical consortium meetings, virtual consortium meetings will be held yearly by videoconference (GoTo Meeting) in between the physical meetings (4 in total). Meetings within each WP will be carried out by videoconference every 2 months (when no consortium meetings occur) and will be led by each WPL and overseen by the PC. Additional ad-hoc meetings will be carried out if necessary. Records from relevant email and teleconference meetings as well as progress reports will be available to all project members in the private intranet of the website.

Table 2: Tentative project physical meetings plan

Meeting	Timing	Place
Kick-off Meeting	May 27 th -28 th , 2019	Zaragoza, Spain
Meeting of the Consortium / General Board	04/2020	Eindhoven, the Netherlands
Review Meeting	06/2020	Brussels, Belgium
Meeting of the Consortium / General Board Exploitation workshop	04/2021	tbd
Review Meeting	12/2021	Brussels, Belgium
Meeting of the Consortium / General Board	04/2022	Tbd



Meeting of the Consortium / General Board dissemination event for a selected audience	04/2023	tbd
Review Meeting	05/2023	Brussels, Belgium

4. EXTERNAL COMMUNICATION AND DISSEMINATION

The effectiveness of reaching the target audience groups and the impact of the communication and dissemination activities will be monitored on a regular basis (Meetings of the General Board, Virtual Meetings). To achieve the potential of the project, differentiation will be made regarding the communication requirements of the various audiences associated with the project.

4.1 Visual identity

4.1.1 Logo

The logo includes the name of the project (PRIME), besides the depiction of the acronym, it shows aspects such as chirality and light, key ingredients for PRIME. The PRIME logo will be used for any (internal or external) deliverable, report or dissemination activity.



4.1.2 Website

The project website was established at the beginning of the project, containing information about PRIME members, objectives and results at every stage, publications, and initiatives of communication & dissemination (C&D). It will be active for, at least, 2 years after the end of the project. The website will be used as an immediate tool for project dissemination, with a particular section devoted to communication to the general public, where the research outcomes and impact will be communicated in plain language for general understanding.

www.project-prime.eu



4.2 Communication and Dissemination activities

All PRIME participants will communicate the project and disseminate project results which represent their legitimate interest by disclosing them to the public by appropriate means unless there are IPR issues to be resolved. WP 4 and 5 manage all communication and dissemination efforts as well as the obligation to protect intellectual property rights (IPR) of project outcomes. Each participant aims for open access to all peer-reviewed scientific publications relating to its results in line with the provisions made under Article 29 and 38 of the GA. Tables 3 and 4 illustrate the initial plan for communication and dissemination activities. All actions listed in the table have been allocated appropriate resources (time and money) and will consider EC conform publication tools (such as DIGITAL.CSIC, CSIC's institutional repository, a top provider of OpenAir and also a complier with all 6 criteria of Re3data (the Registry of Open Data Repositories)). For evaluation of the implemented actions, indicators/metrics have been chosen with an estimated quantitative objective (see tables 3+4). These targets will be periodically reviewed by the consortium.



Table 3: Planned communication activities

Medium and means (timeline and resources)	Purpose and addressed target audience	Evaluation metrics	Implementation plan year 1
Website (M02 until at least 2 year after end of project)	Core of internal and external communication activities to the public provides easy access to project information	Google-based analysis, # website hits, page views, public deliverable/document downloads, costs spent on the activity	Continuous updates of the project website Final setup of internal platform structure until 11/19
Project fact sheets (M08, end of project)	Providing printed project information for dissemination activities such as conferences, meetings and science hotspots	# of fact sheets printed, # of fact sheets distributed (website download), costs spent on the activity	Printed project fact sheet until 12/19 Distribution to all partners until 12/19
Press releases, newsletters (project start, at all major results / press departments of participants, WP4)	Professionally compiled information about the project/results for distribution in (participant's) newsletters and basis for science sections in newspapers	# press releases (downloads from website), # articles based on press releases, costs spent on the activity	Overall project press release compiled until 11/19
Science magazines (project start, at all major results)	Professionally compiled, easy understandable information about the project/results to disseminate information about the project and its results on (inter)national level (e.g. Materials today, Material World, Drug discovery today)	# media communications issued, media interviews, # articles published, # google hits, costs spent on the activity	Set up of implementation plan until 12/19
Direct communication efforts (meetings, email, telephone, letters) (M01 with increasing effort towards the 2 nd half of the project/ WP4)	Contacting relevant public multipliers (e.g. journalists, policy makers) will facilitate to engage the public to follow the project activities	# email responses, contacts network, costs spent on the activity	Set up of implementation plan until 12/19
Public Engagement activities (M01-M48, WP4)	Talks at Open Days in the academic institutions to attract young researchers towards PRIME's disciplines; Visits to e.g., secondary schools even with a gender focus	# of activities carried out, costs spent on the activity	Set up of implementation plan until 12/19



Social media (Start of project with increase towards the 2 nd half of the project / WP4)	Addressing the public with a video, published on e.g. YouTube, targeting the general population	# of views, costs spent on the activity	Set up of implementation plan until 12/19
Reports and deliverables (M01- M48/WP5)	According to the requirements of the EC, demonstrating the project's progress	Target-performance comparison, linking PC/EC, costs spent on the activity	As set in the GA

Table 4: Planned dissemination activities

Medium and means (timeline/resources)	Purpose and addressed target audience	Evaluation metrics	Implementation plan
Website (M02 until at least 2 year after end of project)	Core of internal and external communication activities to the public provides easy access to project information	Google-based analysis, # website hits, page views, public documents downloads, costs spent on the activity	Continuous updates of the project website Final setup of internal platform structure until 11/19
Journal articles (M9 with increasing effort towards the 2 nd half of the project / Resources: WP4 publication fees as budgeted by each participant)	Add scientific credibility to PRIME results by publishing in peer reviewed journals and open research platforms respecting the H2020 obligation for open access publishing: Advanced Materials, Lab on a Chip, Cell, Nature journals	# journal reports and scientific articles submitted and published, type of journal (industry, academic), journal impact factor and circulation; # citations, # editorials based on research reports, costs spent on the activity	Set up of implementation plan until 12/19
Conference presentations, Posters (M9 with an increase towards the 2 nd half of the project / Resources: Travel and conference fees as budgeted by each participant)	Establish connections with industrial, governmental, advocacy or academic opinion leaders, engaging in direct, face-to-face communications choosing stakeholder related events	# (invited) presentations, type of conferences, conference publications, # new contacts, # citations, costs spent on the activity	Set up of implementation plan until 12/19



Project fact sheets (12/19 and end of project (04/23))	Providing printed project information for dissemination activities such as conferences, meetings and science hotspots	# of fact sheets printed, # of fact sheets distributed (website download), costs spent on the activity	Printed project fact sheet until 12/19 Distribution to all partners until 12/19
Press releases, newsletters (project start, at all major results / press departments of participants)	Professionally compiled information about the project/results for distribution in (participant's) newsletters and basis for science journalists	# press releases (downloads from website), # articles based on press releases, costs spent on the activity	Overall project press release compiled until 11/19
Science magazines (project start, at all major results)	Professionally compiled, easy understandable information about the project/results to disseminate information about the project and its results on (inter)national level (e.g. Materials today, Material World, Drug discovery today)	# media communications issued, media interviews, # articles published, # google hits, costs spent on the activity	Set up of implementation plan until 12/19
Direct communication efforts (meetings, email, telephone, letters) (M01 (05/19) with increasing effort towards the 2 nd half of the project/ WP4)	Contacting experts and multipliers (e.g. journalists, policy makers) will facilitate to engage the defined stakeholder groups to follow and engage in the project activities	# email responses, contacts network, costs spent on the activity	Set up of implementation plan until 12/19



5. PUBLICATIONS

5.1 Contractual framework for publications

According to the European Commission, “each beneficiary must, unless it goes against their legitimate interests - as soon as possible - disseminate its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium).

The following paragraphs and their excerpts of the grant agreement are mostly relevant to the obligation to disseminate results:

- ARTICLE 29 — DISSEMINATION OF RESULTS — OPEN ACCESS — VISIBILITY OF EU FUNDING (page 47 of the grant agreement)
- ARTICLE 38 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING (page 55 of the GA)

The following chapter and its excerpts of the CA is mostly relevant to the obligation to disseminate results:

- Section 8.3: Dissemination

6 CONCLUSIONS

This dissemination strategy provides the PRIME project with a solid framework for disseminating project results and activities. The PRIME consortium will use this document as an initial strategy which will be further reviewed, revised and updated as dissemination materials and specific strategies are evaluated for their reach, effectiveness in targeting particular stakeholders and alignment with stakeholder interests and barriers. This document, and more importantly implementation, will be revisited in the meetings of the General Board in light of experience. PRIME poses particular challenges for effective dissemination, given the variety of stakeholders involved.



ANNEX 1: RECENT AND FUTURE ACTIVITIES BY PRIME PARTNERS

Type of activities	Main leader (Owner(s))	Title/Type/Name of event	Date	Country	Type of Audience	Size of audience	Countries addressed
Oral presentation (invited)	CSIC	2nd Spanish Conference on Biomedical Applications of Nanomaterials (SBAN2019)	June 6-7, 2019	Spain	Scientific	100	Spain
Oral presentation (invited)	CSIC	CINBIO, 3rd Annual Meeting. From bench to bedside: diagnosis, therapy and data analysis	July 1-2, 2019	Spain	Scientific	75	Spain
Oral presentation (invited)	CSIC	Controlled Release Society Annual Meeting & Exposition	July 21-24, 2019	Spain	Scientific	900	Spain



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010

Oral presentation	CSIC	Light and Life. 17th International Congress on Photobiology, 18th Congress of the European Society for Photobiology	August 25-30, 2019	Spain	Scientific	350	International
Oral presentation (invited)	CSIC	SPIE Security + Defence 2019	September 8-12, 2019	France	Scientific	75	International
Oral presentation (invited)	CSIC	CIMTEC2020	June 20-23, 2020	Italy	Scientific		International



	CSIC	International Liquid Crystal Elastomers Conference (ILCEC2021)	April 2021	Guangzhou, China	Scientific		International
	UNIZAR	Lab-on-a-Chip and Microfluidics Europe	2021		Scientific		International
	UNIZAR	microTAS	2021		Scientific		International



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010



	UNIZAR	Medica	2021		Companies		International
	UNIZAR	Selectbio Innovations in Microfluidics	2021		Scientific		International



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010

ANNEX 2: STAKEHOLDER ANALYSIS TEMPLATE

Stakeholder group	Specific stakeholders / Contact person	Power/Interest matrix <ul style="list-style-type: none"> • <i>low power and low interest → monitor</i> • <i>high power, low interest → keep satisfied</i> • <i>low power, high interest → keep informed</i> • <i>high power, high interest → Manage Closely</i> 	Support vs. Resistance <ul style="list-style-type: none"> • <i>Unaware</i> • <i>Resistant</i> • <i>Neutral</i> • <i>Supportive</i> • <i>Leading</i> Status: Current (C) / Desired (D)	Driving factors	Engagement strategy



ANNEX 3: NON EXHAUSTIVE LIST OF STRATEGIC/FINANCIAL INVESTORS

Paladin Capital Group, Venrock, M.M. Dillon & Co, Gimv, F-Prime Capital Partners, Bill & Melinda Gates Foundation, BOE Technology Group, Charlotte Angel Fund, Duke Management Company, North Carolina Biotechnology Center, Rex Health Ventures, Upstate Carolina Angel Network, Apex Partners, Mobeus Equity Partners, National Science Foundation, Barclays Investment Bank, Telegraph Hill Partners, European Commission, European Innovation, Oxford Finance Corporation, BioVeda Capital, SPRING Seeds Capital, Greenwood Asset Management, Livzon Pharmaceutical Group, Syno Capital, Stars Innovation, Blackhorn Ventures, Breakout Labs, Dolby Family Ventures, Eastern Capital, Merck Global Health Innovation Fund, Norwich Innovations, Partners Innovation Fund, Persistent Venture Fund, Pacific Channel, Angel HQ, ArcAngels, Enterprise Angels, The ICEHOUSE, EDBI, New Zealand Venture Investment Fund, Novo Holdings, Massachusetts Life Sciences Center, Kodiak Venture Partners, InSightec, Bio-Rad Laboratories, PAAB, Sanford Health, Intuitive Surgical, Occident Group, Polytech Ventures, Redalpine Venture Partners, Zuhlke Ventures AG, Zühlke Ventures AG, Trade Capital Funding, Indie Bio, SOSV, Purdue Research Foundation, VF Venture, Zeeuws Investerings Fonds, Fusion Fund, Human Genome Research Institutes, Keiretsu Forum, Life Science Angels, Mayfield Fund, Signatures Capital, StartX, Tapestri, Tech Coast Angels, Tsingyun Ventures, NetScientific, 5 Prime Ventures, Agilent Technologies, Anzu Partners, Fusion X Ventures, Highlander Venture Fund, Illumina Ventures, Triton Technology, Vertical Venture Partners, Band of Angels, Physic Ventures, Twente Technology Fund, eCoast Angel Network, Qiming Venture Partners, Vivo Capital, Enterprise Ireland, Alloy Ventures, GE Ventures, Mohr Davidow Ventures, Myriad Genetics, Northgate Capital, Quaker Bioventures, Sectoral Asset Management, Technology Venture Partners, Advantage Capital, Cayuga Venture Fund, Gefinor Capital, Limestone Capital Advisors, Onondaga Venture Capital Fund, Rand Capital, Zoetis, Launch Capital, Go Beyond, National Institute of Health, Eurostars, Horizon Discovery, Innovate UK, Parkwalk Advisors, Parkwalk Advisors Ltd, Twist Bioscience, University of Edinburgh, Debiopharm Group, Canon, CARB-X, CRG L.P, Goldman Sachs, IDEX Corporation, Baekeland Funds, Capital-E, Capricorn Venture Partners



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010

ANNEX 4: NON EXHAUSTIVE LIST OF COMPANIES

Akonni Biosystems Inc, Albright Technologies, Inc., ALine, Inc., Applied Biophysics Inc, Applied Biosystems Inc – BioTrove, Arcxis Bio Technologies Inc, Arrayjet, Artemis Health Inc., Axis-Shield PoC, Bartels Mikrotechnik GmbH, Becton Dickinson & Company, Bell Brook Labs Llc, Biodetection Instruments, Biodot Inc, BioFluidix GmbH, Bio Force Nanosciences Holdings, Biolithic, Biomicro Systems Inc, Bionas GmbH, Bio Scale, Biosurfit, BioTray, Biotrove, BioVitesse, Boehringer Ingelheim, microParts GmbH, Boston Microfluidics, Caliper Life Sciences Inc, Cambridge Biomagnetics, Cambridge Consultants Inc, Capilix, CapitalBio Corporation, CEA MINATEC, Cellectricon AB, Cellix, Celula Inc., Centre for Business Innovation, Cepheid, cetoni GmbH, Cidra Precision Services LLC, Claros Diagnostics, Clondiag GmbH, CMC Microsystems, CorSolutions, Coventor, Inc, Creative Microsystems, CSEM Centre Suisse d'Electron. et de Microtechnique, Cyclofluidic, Cynvenio Biosystems, Cytonome Inc, Cytoo, Daktari Diagnostics, Inc., Dalsa Semiconducteur, Debiotech SA, DeltaDot, DEOS Labs, Diagnostics For All, Diagnoswiss SA, Digilab, Inc., DNA Electronics, The Dolomite Centre, Dyconex AG, Edge Embossing, eg technology ltd, Eksigent Technologies, ELVEFLOW, Epigem Ltd, Epocal Inc, EV Group E. Thallner GmbH, Evotec AG, Ambit Biosciences, Artemis Health, Atomo Diagnostics, Baebies, BioSyntagma, Biovitesse, Carterra, Cellix Limited, Celula Inc., Clearbridge Biomedics, Cynvenio Biosystems, Cytocentrics, CytoVale, Daktari Diagnostics, DxNow, Engender Technologies, Engine Biosciences, Esgender Technologies, ioWorks, Bürkert Fluid Control Systems, Axxicon Holding B.V., Yole, Dolomite Microfluidics, RainDance Technologies, Wafergen Biosystems, Fluidigm, Scienion, Fraunhofer, silicon Biosystems, Celsee Diagnostics, Bio Rad, BD, Sony DADC, Stratec, Cytosurge Nanosurf, SphereFluidics, Thinxxs, Ascent Bio-Nano, Zephyrs Biosciences, BioFluidica, nanocollect, mission bio, cytena, iNfinitesimal, LumaCyte, micronit, microfluidics Chipshop, Little things factory, Micralyne, z-microsystems, Translume, Tecnsico, Invenios, CapitalBio, Weidman Plastics, Minifab, Perkin Ellmer, Abaxis Inc, Abbott Point of Care Inc, Achira Labs Pvt Ltd, ACAMP: Alberta Centre For Advanced Mnt Products, ACEA Biosciences, Inc, Advalytix / Beckman Coulter, Advanced Liquid Logic, Advanced Microlabs, Advion Biosciences Inc, Affymetrix Inc, Agilent Technologies, Aixtek, febit biomed GmbH / Comprehensive Biomarker Center, Firefly Bioworks, Fluidigm, Fluidigm Europe BV, Fluidigm Singapore Pte. Ltd., Fluidware Technologies, Fluigent, Fluimedix, Foundry Micro Foundry, FutureChemistry Holding BV, Gene Fluidics, Genewave, GeSIM Ges. für Silizium-Mikrosysteme mbH, GnuBio, Grace Bio-Labs, Gyros AB, Habsel, Helicos Biosciences, ibidi GmbH, IBM Research GmbH, Image Xpert Inc, IMT - Institute of Microchemical Technology, Incept Biosystems, Instep Nanopower LLC, Institut für Mikrotechnik Mainz GmbH, Intellisense Software Corporation, Invenios, ITC MEMS (Infotonics Technology Center), iX-factory GmbH, Jenoptik Laser, Optik Systeme GmbH, Jonsman Innovation, Kryoz Technologies BV, Kumetrix Inc, Labcyte Inc., Labcyte Europe, Fluxion Biosciences, GE Healthcare, GnuBIO, Gradientech, Ingeneron, Luna Innovations, Lunaphore Technologies, Medtronic, mFluIDx, Microfluidic Innovations, Microlytic, Mimetas, Mission Bio, MOF Technologies, NanoCollect Biomedical, OndaVia, On-Q-ity, PhoeniX Software, Platelet BioGenesis, Poly-Pico, RedShift



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010

BioAnalytics, Rheonix, Scandinavian Micro Biodevices, SemiProbe, SensiMed, SFC Fluidics, Sphere Fluidics, Spinomix, T2 Biosystems, Trinean, Labcyte Japan, LabSmith, Leukodx LP, Life Bioscience, Life Technologies Corporation - Ion Torrent Systems Inc, Lionix, Little Things Factory, Luna Innovations Inc, MA3 Solutions B.V., Maxwell Sensors Inc, Medspray, Medtronic Inc, Micro2gen, Microchip Biotechnologies, Micro Chips Inc, Microdrop Technologies, MicroFab Technologies, microfluidic ChipShop GmbH, Microfluidic Innovations, Microfluidic Systems Inc, Microlab Devices, microLIQUID, Microlytic, Micronics Inc, Micronit Microfluidics BV, MicroTEC, MicroTEC, MicruX Fluidic, mikroglas chemtech GmbH, Millipore Research & Development, Millipore Corporation, Minifab, MODE diagnostics, Molecular Vision Ltd, Nanion Technologies, Nano Fusion Technologies, Inc., Nanobiosym, Nanopoint Inc, Nanosphere Inc, Nano-Terra, Next Advance Inc., Pathogenetix, Microvisk, Micromolding Solutions Inc., Medimate B.V., SmallTech Consulting, Zephyrus Biosciences, Synchronicity, Mastering Services, DENZ Bio-Medical, Pacific Biosciences, Thermo Fischer Scientific, 10X Genomics, Proteus Biomedical, Qiagen GmbH, RainDance Technologies, Inc., Richell, Scienion AG, Seahorse Bioscience Inc, Sensimed SA, Silex Microsystems, Siloam Biosciences, SIMTech, Spinx-Technologies, Superior NanoBioSystems, SIMTech - Singapore Institute Of Manufacturing Technology, SurModics, Inc, T2 Biosystems Inc, Takasago Electric, Technobiochip Soc. Consortile A RL, Tekniker, Translume Inc, Tronics Microsystems, US Genomics, Wasatch Microfluidics, Weidmann Plastics Technology North America, YMC Co., Ltd. Microreactor Research Center, Zeta Instruments, Aquula, CardioMEMS, Cellasic Corporation, Fraunhofer USA Center-Manufacturing Innov, Crospon Inc, Focus Diagnostics Inc, Gradientech AB, Cellanyx, Illuminaria, LLC, Fraunhofer ICT-IMM, Innovative Micro Technology, Minitech Machinery, Ingeneron Inc, Mycrolab, On-Q-ity, Optotrack, Osmotex AG, Philips Electronics Nederland B.V., Positive ID Corporation, Pure Slides, Bio-Rad Laboratories Inc, Quorum Technologies, Rheonix Inc, Rheo Sense Inc, Roche Diagnostics Corporation, Rogue Valley Microdevices, SensLab GmbH, SFC Fluidics LLC, Siemens Healthcare Diagnostics, Silicon Biosystems, Smart Holograms, Spectra Fluidics Inc, SphereFluidics, Stanford Microfluidics Foundry, Syrris, Ltd, Tear Lab Corporation, Tecan Systems Inc, Trianja, Veridex, LC, Xennia Technology Ltd, Xona Microfluidics, Wave 80 Bio Sciences Inc, Trinean, uFluidix, Micralyne Inc., z-werkzeugbau-gmbh, FlowJEM, Cytocentrics Bioscience GmbH, Plasma Technology Systems, Carbo Analytics, Drop-Tech, GenePOC, Genspeed Biotech GmbH



PRIME has received Funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. 829010